Document is current
Any future updates will be listed below
-
Authors
Siddiqui, Sameed M. https://orcid.org/0000-0002-0392-7085
Welch, Nicole L.
Nguyen, Tien G.
Razmi, Amaya
Chang, Tianyi
Senft, Rebecca https://orcid.org/0000-0003-0081-4170
Arizti-Sanz, Jon https://orcid.org/0000-0002-4092-9952
Mirhashemi, Marzieh E.
Stirling, David R.
Ackerman, Cheri M.
Cimini, Beth A. https://orcid.org/0000-0001-9640-9318
Blainey, Paul C. https://orcid.org/0000-0002-4889-8783
Sabeti, Pardis C. https://orcid.org/0000-0002-9843-1890
Myhrvold, Cameron https://orcid.org/0000-0002-8971-184X
-
Funding
Funding for this research was provided by:
United States Department of Defense | Defense Advanced Research Projects Agency (D18AC00006, D18AC00006)
U.S. Department of Health & Human Services | Centers for Disease Control and Prevention (75D30122C15113, 75D30122C15113)
Audacious Project is a collaborative funding initiative housed at TED, including The ELMA Foundation, MacKenzie Scott, the Skoll Foundation, and Open Philanthropy
Howard Hughes Medical Institute
- License Information
-
More Information
Article History
Received: 20 August 2023
Accepted: 6 August 2025
First Online: 22 September 2025
Competing interests
: S.M.S., N.L.W., J.A.S., C.A., P.C.B., P.C.S. and C.M. are inventors on pending patent applications related to this work (US patent application no. 2025/0066842 A1; US patent application no. 2022/0228150 A1; international patent application no. 2020/102610 A1; US patent application no. 2021/0102197 A1; US patent application no. 2019/061574), SHINE and multiplexed Cas13 diagnostics. P.C.S. is a co-founder of, shareholder in, and consultant to Sherlock Biosciences, Inc. and Delve Bio. P.C.B. is a consultant to or holds equity in 10X Genomics, General Automation Lab Technologies/Isolation Bio, Celsius Therapeutics, NextGen Diagnostics, Cache DNA, Concerto Biosciences, Stately, Ramona Optics, Bifrost Biosystems, and Amber Bio. His laboratory receives research funding from Calico Life Sciences, Merck, and Genentech for unrelated work. C.M.A. is the CEO and co-founder of Concerto Biosciences. All other authors declare no competing interests.
